Business Wire

NY-AVANTI-ACQUISITION

Share
Avanti Acquisition Corp. Announces Launch of $500,000,000 Initial Public Offering

Avanti Acquisition Corp. (the “Company”), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced the commencement of its initial public offering of 50,000,000 units at a price of $10.00 per unit. The Company is sponsored by Avanti Acquisition SCSp, an affiliate of NNS Group, the private family office of Nassef Sawiris and Sienna Capital, a subsidiary of Groupe Bruxelles Lambert. The Company intends to be sector agnostic and to focus on European family owned or founder led businesses with a US nexus. The units are expected to be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “AVAN.U”. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant. Each whole warrant may be exercised for one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the NYSE under the symbols “AVAN” and “AVAN WS,” respectively.

Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC are serving as the joint book-running managers for the offering. The Company intends to grant the underwriters a 45-day option to purchase up to an additional 7,500,000 units at the initial public offering price to cover over-allotments, if any.

When available, copies of the prospectus may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 1-800-831-9146 or by contacting Mihir Unadkat, Director; telephone: +44 20-7986-0015; email: mihir.unadkat@citi.com and from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282; telephone: 1-866-471-2526; email: Prospectus-ny@ny.email.gs.com .

A registration statement relating to the securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement for the Company’s offering filed with the Securities and Exchange Commission (“SEC”) and the preliminary prospectus included therein. Copies are available on the SEC’s website, www.sec.gov . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Pharm Signs Strategic Trilateral Agreement with Becton Dickinson and BD Korea to Accelerate Global PFS CMO Business17.9.2025 02:00:00 CEST | Press release

Strengthen the PFS CMO business through a long-term partnership with global syringe leader BDExpand the global customer network by leveraging the BD&CMO Partnership ProgramTriple production capacity of the Cheongju plant by 2030, up from the current annual output of 16 million syringes Celltrion Pharm (KOSDAQ: 068706), a South Korean biopharmaceutical firm, said on September 16 that it has inked a strategic trilateral agreement with a multinational syringe manufacturer, Becton Dickinson France S.A.S. (BD), and its Korean branch BD Korea. The signing ceremony took place at Celltrion Pharm’s research center in Songdo, Incheon, with its President Yoo Young-ho in attendance alongside key officials from BD and BD Korea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250914960476/en/ From left: Jeffrey Chen, Vice President, BD (Becton Dickinson) Greater Asia; Yoo Young-ho, President, Celltrion Pharm; and Jason Hwang, Country Gener

Mirion Partners with IAEA to Enhance Radiation Safety on a Global Scale16.9.2025 23:19:00 CEST | Press release

Partnership Agreement to Strengthen Radiation Detection and Measurement Capabilities at the Terrestrial Environmental Radiochemistry (TERC) Laboratory, Safeguarding the Environment and Promoting Nuclear Safety Mirion (NYSE: MIR), a leading provider of advanced radiation safety solutions, has signed a partnership agreement and practical arrangements with the International Atomic Energy Agency (IAEA), the world’s central intergovernmental forum for scientific and technical cooperation in the nuclear field, to cooperate in the area of radiation detection and measurement. Through this collaboration, Mirion’s advanced instrumentation and profound understanding of ionizing radiation will combine with the IAEA’s expertise and influence to advance the safe and secure use of nuclear technology worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916693003/en/ Mirion Chairman of the Board and CEO Thomas Logan and IAEA Director

NIQ and Displayce Collaborate to Bring Sales Lift Measurement to Europe’s DOOH Advertising Market16.9.2025 18:00:00 CEST | Press release

NIQ, a leading consumer intelligence company, and Displayce, a pioneering specialist technology suite for Out-of-Home advertising, are collaborating to bring advanced measurement capabilities to the European DOOH market. By combining NIQ’s trusted consumer intelligence with data from Displayce’s media activation platform, advertisers can link DOOH campaigns to in-store sales performance — driving transparency and accountability across the DOOH ecosystem. NIQ has long been a trusted source of consumer purchase insights for manufacturers and retailers, capturing the buying behavior of millions of households across more than 90 countries. Now, NIQ is extending its expertise and insights into the media ecosystem, empowering advertisers and agencies with new data assets and measurement solutions to improve their understanding of consumers and drive better ROI. Through the collaboration, NIQ and Displayce are driving the DOOH ecosystem toward more addressable, transparent, and results-driven

Capcom’s Resident Evil Requiem, the Latest Title in the Series, Also Coming to Nintendo Switch 2 on February 27, 2026!16.9.2025 15:00:00 CEST | Press release

– Additionally, two other Resident Evil series titles to be released for the console on the same date in step with Capcom’s multi-platform strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series scheduled for release on February 27, 2026, for PlayStation®5 system, Xbox Series X|S, and PC, will also be released for Nintendo Switch™ 2 at launch. In addition, Resident Evil 7 biohazard and Resident Evil Village, two other titles in the series, will also be released for Nintendo Switch 2 on the same date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916064724/en/ Resident Evil Requiem Key Art Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development experience cultivated over numerou

Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production16.9.2025 15:00:00 CEST | Press release

Human insight and autonomous agents work together to transform operations, enhance efficiency, improve safety, and unlock new value across the enterprise. Aker BP, one of Europe's largest independent oil companies, and Cognite, the global leader in industrial AI, deepen their strategic partnership through the expanded adoption of Cognite Atlas AI™,harnessing the power of AI agents to improve efficiency, reduce costs, and elevate productivity. This enhanced collaboration puts Aker BP at the forefront of leveraging agentic AI to drive significant value and transform its operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903134233/en/ Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production Aker BP's "AI-first strategy" was developed to help lead the energy sector into a data-driven future by seamlessly integrating AI applications within industrial settings and business objectiv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye